Clinical Trials Logo
  1. Home
  2. Sjögren Syndrome
  3. NCT04035668

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome — LOUiSSe  

Sjögren Syndrome Clinical Trial

Official title:
An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)

Clinical Trial Summary

This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome. LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor.

Clinical Trial Description

This study was planned as an adaptive Phase 2 randomized, double-blind, placebo-controlled, multi-center, integrated dose-ranging study to evaluate the safety and efficacy of multiple remibrutinib doses in patients with moderate to severe Sjögren's Syndrome. Of the initially planned two parts, only Part 1 of the study was conducted. In Part 1, the highest expected biologically active single dose of remibrutinib (100 mg) was tested in two different dosing regimens, a once daily dose (qd) or twice daily dose (bid), and compared to the placebo group. Each patient in Part 1 of the study underwent a screening period of up to 6 weeks, a treatment period of 24 weeks, and a follow-up period of 30 days post-treatment before the End of Study (EOS) visit. The total duration for each patient in the study, including Screening, was up to 35 weeks. For the treatment period, patients were randomized in a 1:1:1 ratio to one of the 3 treatment groups: remibrutinib 100 mg bid, remibrutinib 100 mg qd and placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04035668
Study type Interventional
Source Novartis
Contact
Status Terminated
Phase Phase 2
Start date July 12, 2019
Completion date November 23, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02752269 - Early Detection of Pulmonary- and Pulmonary Vascular Disease in Sjögren Syndrome
Completed NCT05079581 - Pelvic Floor Exercises in Patients With Sjögren's N/A
Completed NCT03905525 - Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome Phase 2
Completed NCT04819269 - Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome Phase 3
Completed NCT02011776 - A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome N/A
Recruiting NCT06411132 - Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
Completed NCT03762824 - Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Phase 4
Completed NCT02049112 - A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Phase 4
Recruiting NCT04848870 - Dental and Periodontal Status of Patients With Sjögren's Syndrome.
Completed NCT03941184 - Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Completed NCT03608761 - Comparison Between Rebamipide 2% Versus Autologous Serum Phase 4
Active, not recruiting NCT04793646 - N-acetylcysteine for Primary Sjögren's Syndrome N/A